2022 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML) ¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö : 2022-04-30±³À°ÀÏÀÚ : 2022-04-30
±³À°Àå¼Ò : °æÁÖ ´õÄÉÀÌÈ£ÅÚ
±³À°ÁÖÁ¦ :
2022 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML) ¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸¸¼º°ñ¼ö¼º¹éÇ÷º´¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
°æ»óºÏµµ±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-30 AȦ 09:30~09:50 What will be the next beyond transplantation and TKIs(Tyrosine kinase inhibitor)? ±èÇõ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 04-30 AȦ 09:50~10:15 TKI discontinuation and strategies to increase the number of eligible patients. ±è°æÇÏ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 04-30 AȦ 10:15~10:40 Life-long TKI therapy, including management of cardiovascular risk factors and other toxicities °øÁöÇö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-30 AȦ 10:40~11:05 Advanced phase CML(hronic Myelogenous Leukemia) and the management of accelerated and blast phase disease. À̼ºÀº(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-30 AȦ 11:15~11:40 Basic/translational research ÇÑÀçÁØ(°æÈñÀÇ´ë)
±³À°½Ã°£ 04-30 AȦ 11:40~12:00 Clinical research I ±è»ó¾Æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-30 AȦ 12:00~12:20 Clinical research II Á¶ÈñÁ¤(°æºÏÀÇ´ë)
±³À°½Ã°£ 04-30 AȦ 12:20~12:40 CML(hronic Myelogenous Leukemia) working parth research progress ¾öÁöÀº(ÇѾçÀÇ´ë)